Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection

• Verfasst von: Gerhards, Catharina [VerfasserIn]
• Verfasst von: Thiaucourt, Margot [VerfasserIn]
• Verfasst von: Kittel, Maximilian [VerfasserIn]
• Verfasst von: Becker, Celine [VerfasserIn]
• Verfasst von: Ast, Volker [VerfasserIn]
• Verfasst von: Hetjens, Michael [VerfasserIn]
• Verfasst von: Neumaier, Michael [VerfasserIn]
• Verfasst von: Haselmann, Verena [VerfasserIn]
• Titel: Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection
• Verf.angabe: Catharina Gerhards, Margot Thiaucourt, Maximilian Kittel, Celine Becker, Volker Ast, Michael Hetjens, Michael Neumaier, Verena Haselmann
• E-Jahr: 2021
• Jahr: June 2021
• Umfang: 7 S.
• Fussnoten: Gesehen am 28.08.2021
• Titel Quelle: Enthalten in: International journal of infectious diseases
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 1997
• Jahr Quelle: 2021
• Band/Heft Quelle: 107(2021), Seite 221-227
• ISSN Quelle: 1878-3511
• DOI: doi:10.1016/j.ijid.2021.04.080
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Anti-SARS-CoV-2 antibodies
• Sach-SW: Antibody dynamics
• Sach-SW: Antibody kinetics
• Sach-SW: Longitudinal assessment
• Sach-SW: Post-COVID syndrome
• Sach-SW: Serological immune response
• K10plus-PPN: 1767848552

Abstract

Introduction - The longevity of antibody levels against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the duration of immunity are current topics of major scientific interest. Antibody kinetics during the acute phase are well studied, whereas the long-term kinetics are yet to be determined, with contradictory results from the studies to date. Here, we present a longitudinal analysis of the serological responses to a SARS-CoV-2 infection following convalescence and the association with post-COVID syndrome (PCS). - Materials and methods - A total of 237 serum samples were prospectively collected from 61 participants who had had a SARS-CoV-2 infection, which was confirmed using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). For each participant, anti-nucleocapsid (N) and anti-spike subunit 1 receptor binding domain (RBD/S1) immunoglobulin (Ig) levels were regularly determined over a period of 8 months. COVID-19-associated symptoms were assessed using a standardized questionnaire at study entry and again after 6 months. - Results - Antibodies were detectable in 56 of the 61 participants. No substantial decline in anti-SARS-CoV-2 pan-Ig levels was observed for the duration of the follow-up period. Antibody levels correlated positively with the disease severity, body mass index, fever, and smoking status. It was found that 46.8% of the participants suffered from PCS, with olfactory and gustatory dysfunctions being the most commonly reported symptoms. - Conclusion - The results demonstrate stable anti-SARS-CoV-2 antibody titers and thus may indicate a long-lasting immunity. The results are in line with recently published data and provide further insight concerning asymptomatic to mildly-affected patients, the association with clinical features, and the frequency of PCS.